İhsan Kaplan, Ferat Kepenek, Yunus Güzel, Canan Can, Halil Kömek
{"title":"68Ga FAPI-04和18F-FDG PET/CT在不同类型肿瘤肝转移中的作用","authors":"İhsan Kaplan, Ferat Kepenek, Yunus Güzel, Canan Can, Halil Kömek","doi":"10.1055/a-2127-7699","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We compared the diagnostic accuracies of <sup>68</sup>Ga FAPI-04 PET/CT and <sup>18</sup>F-FDG PET/CT for detecting liver metastases (LMs) in patients with different cancer types.</p><p><strong>Materials and methods: </strong>This retrospective study included 63 patients with liver lesions who underwent <sup>18</sup>F-FDG PET/CT and <sup>68</sup>Ga-FAPI-04 PET/CT between May 2020 and May 2022. Patients with histopathologically confirmed primary diagnoses, data that could be accessed retrospectively, liver lesions confirmed by biopsy over at least 3-6 months of follow-up (via ultrasonography, CT, magnetic resonance imaging, PET/CT, or laboratory tests) were included. Patients with secondary malignancies or primary liver malignancies, and/or who could not be followed-up, were excluded.</p><p><strong>Results: </strong>Of the 63 total patients, 34 (54%) were female, and the mean age was 61 (30-92) years. There were 582 LMs in 51 patients and 35 benign liver lesions in 20 (12 patients had only benign and 8 both benign and malignant lesions). Of the 582 LMs, 472 (81.1%) evidenced <sup>18</sup>F-FDG uptake and 572 (98.2%) <sup>68</sup>Ga-FAPI uptake. The diagnostic accuracies of <sup>68</sup>Ga-FAPI PET/CT and <sup>18</sup>F-FDG PET/CT were 98% and 82%, respectively (p < 0.001; McNemar test). When the LMs were compared, the maximum standardized uptake (SUVmax) value was significantly higher on <sup>18</sup>F-FDG PET/CT than <sup>68</sup>Ga-FAPI PET/CT (median: 6.0 vs. 5.4; p = 0.016). However, the LM-to-background ratio (TBR) was significantly higher on <sup>68</sup>Ga-FAPI PET/CT than <sup>18</sup>F-FDG PET/CT (median: 4.1 vs. 2.1; p < 0.001).</p><p><strong>Conclusion: </strong><sup>68</sup>Ga-FAPI PET/CT detected more LMs than did <sup>18</sup>F-FDG PET/CT, and TBR was significantly higher on <sup>68</sup>Ga-FAPI PET/CT than <sup>18</sup>F-FDG PET/CT.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 4","pages":"252-259"},"PeriodicalIF":1.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The Role of 68Ga FAPI-04 and 18F-FDG PET/CT in Detecting Liver Metastases in Different Types of Cancer.\",\"authors\":\"İhsan Kaplan, Ferat Kepenek, Yunus Güzel, Canan Can, Halil Kömek\",\"doi\":\"10.1055/a-2127-7699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>We compared the diagnostic accuracies of <sup>68</sup>Ga FAPI-04 PET/CT and <sup>18</sup>F-FDG PET/CT for detecting liver metastases (LMs) in patients with different cancer types.</p><p><strong>Materials and methods: </strong>This retrospective study included 63 patients with liver lesions who underwent <sup>18</sup>F-FDG PET/CT and <sup>68</sup>Ga-FAPI-04 PET/CT between May 2020 and May 2022. Patients with histopathologically confirmed primary diagnoses, data that could be accessed retrospectively, liver lesions confirmed by biopsy over at least 3-6 months of follow-up (via ultrasonography, CT, magnetic resonance imaging, PET/CT, or laboratory tests) were included. Patients with secondary malignancies or primary liver malignancies, and/or who could not be followed-up, were excluded.</p><p><strong>Results: </strong>Of the 63 total patients, 34 (54%) were female, and the mean age was 61 (30-92) years. There were 582 LMs in 51 patients and 35 benign liver lesions in 20 (12 patients had only benign and 8 both benign and malignant lesions). Of the 582 LMs, 472 (81.1%) evidenced <sup>18</sup>F-FDG uptake and 572 (98.2%) <sup>68</sup>Ga-FAPI uptake. The diagnostic accuracies of <sup>68</sup>Ga-FAPI PET/CT and <sup>18</sup>F-FDG PET/CT were 98% and 82%, respectively (p < 0.001; McNemar test). When the LMs were compared, the maximum standardized uptake (SUVmax) value was significantly higher on <sup>18</sup>F-FDG PET/CT than <sup>68</sup>Ga-FAPI PET/CT (median: 6.0 vs. 5.4; p = 0.016). However, the LM-to-background ratio (TBR) was significantly higher on <sup>68</sup>Ga-FAPI PET/CT than <sup>18</sup>F-FDG PET/CT (median: 4.1 vs. 2.1; p < 0.001).</p><p><strong>Conclusion: </strong><sup>68</sup>Ga-FAPI PET/CT detected more LMs than did <sup>18</sup>F-FDG PET/CT, and TBR was significantly higher on <sup>68</sup>Ga-FAPI PET/CT than <sup>18</sup>F-FDG PET/CT.</p>\",\"PeriodicalId\":19238,\"journal\":{\"name\":\"Nuklearmedizin-nuclear Medicine\",\"volume\":\"62 4\",\"pages\":\"252-259\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuklearmedizin-nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2127-7699\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2127-7699","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
The Role of 68Ga FAPI-04 and 18F-FDG PET/CT in Detecting Liver Metastases in Different Types of Cancer.
Objective: We compared the diagnostic accuracies of 68Ga FAPI-04 PET/CT and 18F-FDG PET/CT for detecting liver metastases (LMs) in patients with different cancer types.
Materials and methods: This retrospective study included 63 patients with liver lesions who underwent 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT between May 2020 and May 2022. Patients with histopathologically confirmed primary diagnoses, data that could be accessed retrospectively, liver lesions confirmed by biopsy over at least 3-6 months of follow-up (via ultrasonography, CT, magnetic resonance imaging, PET/CT, or laboratory tests) were included. Patients with secondary malignancies or primary liver malignancies, and/or who could not be followed-up, were excluded.
Results: Of the 63 total patients, 34 (54%) were female, and the mean age was 61 (30-92) years. There were 582 LMs in 51 patients and 35 benign liver lesions in 20 (12 patients had only benign and 8 both benign and malignant lesions). Of the 582 LMs, 472 (81.1%) evidenced 18F-FDG uptake and 572 (98.2%) 68Ga-FAPI uptake. The diagnostic accuracies of 68Ga-FAPI PET/CT and 18F-FDG PET/CT were 98% and 82%, respectively (p < 0.001; McNemar test). When the LMs were compared, the maximum standardized uptake (SUVmax) value was significantly higher on 18F-FDG PET/CT than 68Ga-FAPI PET/CT (median: 6.0 vs. 5.4; p = 0.016). However, the LM-to-background ratio (TBR) was significantly higher on 68Ga-FAPI PET/CT than 18F-FDG PET/CT (median: 4.1 vs. 2.1; p < 0.001).
Conclusion: 68Ga-FAPI PET/CT detected more LMs than did 18F-FDG PET/CT, and TBR was significantly higher on 68Ga-FAPI PET/CT than 18F-FDG PET/CT.
期刊介绍：
Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar.
Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.
Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.
Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
